Discontinued drug therapies to treat diabetes in 2014

Colca, Jerry R.

doi:10.1517/13543784.2015.1058777

Cited by 6 publications

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 67 P-11187 was described as an oral, highly selective and potent partial agonist of human, rat and mouse GPCR40 with effective concentration 50 (EC 50 ) value of 14.4, 2.53 and 4.25 nM, respectively. 68 P-1736-50 was considered as a PPAR-γ activator, but in preclinical studies, it failed to demonstrate its efficacy and hence was discontinued from further research. Piramal Life Sciences also discontinued the development of diacylglycerol acyltransferase 1 inhibitor P-7435 due to business focus.…”

Section: Introductionmentioning

confidence: 99%

Past and current perspective on new therapeutic targets for Type-II diabetes

Mahajan

Patil

Chaudhari

et al. 2017

DDDT

View full text Add to dashboard Cite

Loss of pancreatic β-cell function is a hallmark of Type-II diabetes mellitus (DM). It is a chronic metabolic disorder that results from defects in both insulin secretion and insulin action. Recently, United Kingdom Prospective Diabetes Study reported that Type-II DM is a progressive disorder. Although, DM can be treated initially by monotherapy with oral agent; eventually, it may require multiple drugs. Additionally, insulin therapy is needed in many patients to achieve glycemic control. Pharmacological approaches are unsatisfactory in improving the consequences of insulin resistance. Single therapeutic approach in the treatment of Type-II DM is unsuccessful and usually a combination therapy is adopted. Increased understanding of biochemical, cellular and pathological alterations in Type-II DM has provided new insight in the management of Type-II DM. Knowledge of underlying mechanisms of Type-II DM development is essential for the exploration of novel therapeutic targets. Present review provides an insight into therapeutic targets of Type-II DM and their role in the development of insulin resistance. An overview of important signaling pathways and mechanisms in Type-II DM is provided for the better understanding of disease pathology. This review includes case studies of drugs that are withdrawn from the market. The experience gathered from previous studies and knowledge of Type-II DM pathways can guide the anti-diabetic drug development toward the discovery of clinically viable drugs that are useful in Type-II DM.

show abstract

Section: Introductionmentioning

confidence: 99%

Past and current perspective on new therapeutic targets for Type-II diabetes

Mahajan

Patil

Chaudhari

et al. 2017

DDDT

View full text Add to dashboard Cite

show abstract

Anti-diabetes Research in India: Contributions from Industrial Organizations

Pal¹,

Pal

2021

Drug Discovery and Drug Development

View full text Add to dashboard Cite

Modelling metabolic diseases and drug response using stem cells and organoids

Lazar

2022

Nat Rev Endocrinol

View full text Add to dashboard Cite

Metabolic diseases, including obesity, diabetes mellitus and cardiovascular disease, are a major threat to health in the modern world, but efforts to understand the underlying mechanisms and develop rational treatments are limited by the lack of appropriate human model systems. Notably, advances in stem cell and organoid technology allow the generation of cellular models that replicate the histological, molecular and physiological properties of human organs. Combined with marked improvements in gene editing tools, human stem cells and organoids provide unprecedented systems for studying mechanisms of metabolic diseases. Here, we review progress made over the past decade in the generation and use of stem cell-derived metabolic cell types and organoids in metabolic disease research, especially obesity and liver diseases. In particular, we discuss the limitations of animal models and the advantages of stem cells and organoids, including their application to metabolic diseases. We also discuss mechanisms of drug action, understanding the efficacy and toxicity of existing therapies, screening for new treatments and pursuing personalized therapies. We highlight the potential of combining stem cell-derived organoids with gene editing and functional genomics to revolutionize the approach to finding treatments for metabolic diseases.

show abstract

Discontinued drug therapies to treat diabetes in 2014

Cited by 6 publications

References 17 publications

Past and current perspective on new therapeutic targets for Type-II diabetes

Past and current perspective on new therapeutic targets for Type-II diabetes

Anti-diabetes Research in India: Contributions from Industrial Organizations

Modelling metabolic diseases and drug response using stem cells and organoids

Contact Info

Product

Resources

About